Egetis Therapeutics AB (LTS:0ABW) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


LTS:0ABW Egetis Therapeutics AB LTS:0ABW
58 GF Score
Price kr6.19
GF Value kr5.59
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Egetis Therapeutics AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0ABW vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egetis Therapeutics AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0ABW
58GF Score
Egetis Therapeutics AB LTS:0ABW
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.19 is trading 10.7% above its estimated GF Value™ of kr5.59. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for LTS:0ABW:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr5.59 vs. price of kr6.19 (10.7% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
58GF Score

Get the complete analysis for LTS:0ABW

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.19
Price
kr5.59
GF Value